| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | Phospholipase A2, Group IB phospholipase A2, Phosphatidylcholine 2-acylhydrolase 1B, PLA2G1B, PLA2, PLA2A, PPLA2 |
| Entrez GeneID | 5319 |
| WB Predicted band size | 16.4kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This PLA2G1B antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 116-145 amino acids from the C-terminal region of human PLA2G1B. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3-4条关于JAK2抗体的参考文献及简要摘要：
1. **《JAK2 mutations in myeloproliferative disorders》**
- **作者**: James C, et al.
- **摘要**: 该文献首次报道JAK2 V617F突变在骨髓增殖性肿瘤(如真性红细胞增多症)中的关键作用，揭示了JAK2抗体在诊断突变相关疾病中的应用价值。
2. **《Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders》**
- **作者**: Baxter EJ, et al.
- **摘要**: 研究通过JAK2特异性抗体检测，证实JAK2突变导致组成性激活的JAK-STAT信号通路，成为骨髓增殖性疾病的重要分子标志物。
3. **《Role of JAK2 in the pathogenesis and therapy of myeloproliferative neoplasms》**
- **作者**: Levine RL, et al.
- **摘要**: 综述总结了JAK2抗体在疾病分型中的作用，并探讨针对JAK2的靶向药物(如鲁索替尼)如何通过抑制异常信号通路改善患者预后。
4. **《JAK and STAT signaling molecules in immunoregulation and immune-mediated disease》**
- **作者**: O'Shea JJ, et al.
- **摘要**: 分析了JAK2抗体在自身免疫性疾病研究中的意义，强调其在调控促炎因子(如IL-6)信号传导中的机制，为开发JAK抑制剂提供理论依据。
(注：以上文献为示例，实际引用时需核对具体发表信息及摘要内容。)
JAK2 (Janus kinase 2) is a cytoplasmic tyrosine kinase critical for signaling pathways of cytokine receptors, including erythropoietin, thrombopoietin, and granulocyte-colony stimulating factor. It plays a key role in hematopoiesis, immune regulation, and cell growth. The JAK2 V617F mutation, identified in 2005. causes constitutive activation of the kinase, leading to uncontrolled cell proliferation. This mutation is strongly associated with myeloproliferative neoplasms (MPNs), such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Anti-JAK2 antibodies are tools used in research and diagnostics to detect JAK2 protein expression or specific mutations. In clinical settings, detecting JAK2 V617F via antibody-based assays (e.g., ELISA, immunohistochemistry) or molecular techniques aids in diagnosing MPNs and differentiating them from reactive conditions. Additionally, JAK2 antibodies are employed in studying signaling mechanisms, drug development, and monitoring therapeutic responses.
Therapeutic JAK inhibitors (e.g., ruxolitinib) target hyperactive JAK2 pathways, highlighting the protein's clinical relevance. However, wild-type JAK2 is essential for normal hematopoiesis, complicating targeted therapies. Research continues to explore isoform-specific antibodies and mutation-selective inhibitors to improve diagnostic accuracy and treatment outcomes while minimizing off-target effects.
×
